Dr Brown on the Potential for Pirtobrutinib to Address Treat

Jennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia.

Related Keywords

, Jenniferr Brown , Chronic Lymphocytic Leukemia Center , Dana Farber Cancer Institute , Harvard Medical School , Margaret Collette Professor , Hematologic Oncology , Cll , Dbtk , Pirtobrutinib , Ash Annual Meeting , Genomics , Chronic Lymphocytic Leukemia , Jennifer Brown , D , Phd ,